MedTrace Logo

The Procalcitonin and Survival Study

NCT00271752 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2010-03-04

No results posted yet for this study

Summary

This is a randomised, single blinded, multicentre trial to evaluate whether daily procalcitonin (PCT) measurements and immediate diagnostic and therapeutic responses to abnormal values and day-to-day changes can reduce the mortality of critically ill patients in the Intensive Care Unit (ICU).

Conditions

  • Localized Infection
  • Sepsis
  • Multiple Organ Failure

Interventions

PROCEDURE

Earlier therapeutic changes regarding infection

For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified

Sponsors & Collaborators

  • Copenhagen HIV Programme

    collaborator OTHER_GOV

  • Danish Research Agency

    collaborator OTHER

  • Hvidovre University Hospital

    collaborator OTHER

  • Danish Procalcitonin Study Group

    lead OTHER

Principal Investigators

  • Jens-Ulrik S Jensen, MD, PhD · Dept. of Clinical Microbiology, Hvidovre University Hospital & Copenhagen HIV Programme (CHIP), Faculty of Health Sciences, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00271752 on ClinicalTrials.gov